MedTrace Logo

MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States

NCT03311295 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-04-28

No results posted yet for this study

Summary

The objective of the study is to evaluate the safety and feasibility of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).

Conditions

  • Mitral Valve Insufficiency

Interventions

DEVICE

ARTO System

The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.

Sponsors & Collaborators

  • Mvrx, Inc.

    lead INDUSTRY

Principal Investigators

  • Reginald Low, MD · University California Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2021-04-26
Completion
2021-04-26
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03311295 on ClinicalTrials.gov